prikaz prve stranice dokumenta Siponimod treatment of patients with multiple sclerosis at the Department of neurology in Split
  Download
PDF 454.09 KB
master's thesis
Siponimod treatment of patients with multiple sclerosis at the Department of neurology in Split
2024. urn:nbn:hr:171:980857
Häggtoft, Walina Lydia
University of Split
School of Medicine

Cite this document

Häggtoft, W. L. (2024). Siponimod treatment of patients with multiple sclerosis at the Department of neurology in Split (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:980857

Häggtoft, Walina Lydia. "Siponimod treatment of patients with multiple sclerosis at the Department of neurology in Split." Master's thesis, University of Split, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:171:980857

Häggtoft, Walina Lydia. "Siponimod treatment of patients with multiple sclerosis at the Department of neurology in Split." Master's thesis, University of Split, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:171:980857

Häggtoft, W. L. (2024). 'Siponimod treatment of patients with multiple sclerosis at the Department of neurology in Split', Master's thesis, University of Split, School of Medicine, accessed 21 December 2024, https://urn.nsk.hr/urn:nbn:hr:171:980857

Häggtoft WL. Siponimod treatment of patients with multiple sclerosis at the Department of neurology in Split [Master's thesis]. Split: University of Split, School of Medicine; 2024 [cited 2024 December 21] Available at: https://urn.nsk.hr/urn:nbn:hr:171:980857

W. L. Häggtoft, "Siponimod treatment of patients with multiple sclerosis at the Department of neurology in Split", Master's thesis, University of Split, School of Medicine, Split, 2024. Available at: https://urn.nsk.hr/urn:nbn:hr:171:980857

Please login to the repository to save this object to your list.
Metadata
TitleSiponimod treatment of patients with multiple sclerosis at the Department of neurology in Split
Title (croatian)Liječenje siponimodom bolesnika s multiplom sklerozom na Klinici neurologije u Splitu
AuthorWalina Lydia Häggtoft
MentorSanda Pavelin (mentor)
Committee memberIvica Bilić (predsjednik povjerenstva)
Committee memberKrešimir Čaljkušić (član povjerenstva)
Committee memberDoris Rušić (član povjerenstva)
GranterUniversity of Split
School of Medicine
Split
Defense date and country2024-07-08, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract
Objective: This study aimed to evaluate the adverse effects of the only approved drug for SPMS treatment in the Split Dalmatian municipality. This was achieved by assessing changes in EDSS scores, lymphocyte counts before and after therapy, MRI findings, and reported adverse effects. Materials and Methods: This retrospective study included 14 patients with SPMS. All participants had been on a siponimod for at least six months. Data collected included demographics and parameters such as EDSS scores, lymphocyte counts, and new CNS lesions. EDSS scores and lymphocyte counts before and after treatment were analyzed at different times (pre-treatment, within one year of treatment, and current EDSS scores). Results: The study included 12 females (85.7%) and two males (14.3%), with a Median age baseline of 60. The baseline EDSS score ranged from 3.5 to 8. The median EDSS scores slightly increased from baseline after the first year of Siponimod treatment from 6 to 6.25. Results showed that the Wilcoxon test was statistically significant, with a W = 0 and P = 0.026, for the EDSS pre-treatment score compared with the current EDSS score. This indicates progressive disability despite ongoing siponimod therapy. Six participants showed a significant increase in the EDSS scores (≥ 0.5), which has clinical significance. Adverse effects were predominately seen in hepatic and gastrointestinal systems. Conclusion: There was an increased disability in patients despite the use of siponimod, with some patients showing unchanged neurological status. Early therapy is recommended in SPMS, and further research encourages the exploration of parameters that affect treatment outcomes.
Abstract (croatian)
Ciljevi: Ovo istraživanje imalo je za cilj procijeniti nuspojave jedinog odobrenog lijeka za liječenje SPMS-a u Splitsko-dalmatinskoj županiji. To je postignuto procjenom promjena u EDSS rezultatima, broju limfocita prije i poslije terapije, MRI nalazima i prijavljenim nuspojavama. Pacijenti i metode: Ova retrospektivna studija uključila je 14 pacijenata sa SPMS-om. Svi su sudionici bili na siponimodu najmanje šest mjeseci. Prikupljeni podaci uključivali su demografske podatke i parametre kao što su EDSS rezultati, broj limfocita i nove lezije CNS-a. EDSS rezultati i brojevi limfocita prije i poslije tretmana analizirani su u različitim vremenima (prije tretmana, unutar jedne godine od tretmana i trenutni EDSS rezultati). Rezultati: Studija je uključivala 12 žena (85.7%) i 2 muškarca (14.3%), s početnom srednjom dobi od 66 godina. Osnovni EDSS rezultat bio je u rasponu od 3,5 do 8. Medijan EDSS rezultata neznatno je porastao u odnosu na početni rezultat nakon prve godine liječenja Siponimodom sa 6 na 6,25. Rezultati su pokazali da je Wilcoxonov rang s predznakom bio statistički značajan, s W = 0 i P = 0,026, za EDSS rezultat prije tretmana u usporedbi s trenutnim EDSS rezultatom. To ukazuje na progresivnu onesposobljenost unatoč kontinuiranoj terapiji siponimodom. Šest sudionika pokazalo je značajno povećanje EDSS rezultata (≥ 0,5), što ima kliničku važnost. Nuspojave su uglavnom uočene u jetrenom i gastrointestinalnom sustavu. Zaključak: Došlo je do povećanja invaliditeta u bolesnika unatoč primjeni siponimoda s tim da su neki bolesnici pokazali nepromijenjen neurološki status. U SPMS-u se preporučuje rana terapija, a daljnja istraživanja potiču na istraživanje parametara koji utječu na ishod liječenja.
Keywords
Keywords (croatian)
Languageenglish
URN:NBNurn:nbn:hr:171:980857
Study programmeTitle: Medical Studies in English
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Embargo expiration date: 2024-07-08
Terms of useLicence In copyright icon
Created on2024-07-04 13:13:02